TG Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TGTX and other ETFs, options, and stocks.

About TGTX

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. 

CEO
Michael Sean Weiss
CEOMichael Sean Weiss
Employees
399
Employees399
Headquarters
Morrisville, North Carolina
HeadquartersMorrisville, North Carolina
Founded
1993
Founded1993
Employees
399
Employees399

TGTX Key Statistics

Market cap
7.58B
Market cap7.58B
Price-Earnings ratio
16.75
Price-Earnings ratio16.75
Dividend yield
Dividend yield
Average volume
2.40M
Average volume2.40M
High today
$50.39
High today$50.39
Low today
$47.98
Low today$47.98
Open price
$48.02
Open price$48.02
Volume
2.55M
Volume2.55M
52 Week high
$50.41
52 Week high$50.41
52 Week low
$25.28
52 Week low$25.28

Stock Snapshot

As of today, TG Therapeutics(TGTX) shares are valued at $49.25. The company's market cap stands at 7.58B, with a P/E ratio of 16.75.

On 2026-06-12, TG Therapeutics(TGTX) stock moved within a range of $47.98 to $50.39. With shares now at $49.25, the stock is trading +2.6% above its intraday low and -2.3% below the session's peak.

Trading activity shows a volume of 2.55M, compared to an average daily volume of 2.4M.

The stock's 52-week range extends from a low of $25.28 to a high of $50.41.

The stock's 52-week range extends from a low of $25.28 to a high of $50.41.

TGTX News

TipRanks 4h
TG Therapeutics Shareholders Reject Executive Compensation at Meeting

TG Therapeutics ( (TGTX) ) has provided an update. At its 2026 Annual Meeting held online on June 11, 2026, TG Therapeutics reported that stockholders represen...

Simply Wall St 22h
TG Therapeutics Is Up 18.5% After Positive Subcutaneous BRIUMVI Phase 1 Data Is Released - simplywall.st

...

TG Therapeutics Is Up 18.5% After Positive Subcutaneous BRIUMVI Phase 1 Data Is Released - simplywall.st
Nasdaq 2d
TG Therapeutics Soars 7.5%: Is Further Upside Left in the Stock?

TG Therapeutics TGTX shares ended the last trading session 7.5% higher at $46.62. The jump came on an impressive volume with a higher-than-average number of sha...

TG Therapeutics Soars 7.5%: Is Further Upside Left in the Stock?

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
12.5%
Sell
12.5%

People also own

Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.